Bausch + Lomb (NYSE:BLCO) PT Raised to $23.00 at Wells Fargo & Company

Bausch + Lomb NYSEBLCO is a publicly traded company that operates in the healthcare industry. The company produces and sells medical devices, pharmaceuticals, and contact lenses. On Thursday, Wells Fargo & Company issued a report on the stock, raising its price objective from $21.00 to $23.00. This means that the brokerage firm now believes that the stock is undervalued and has the potential for growth.

Wells Fargo & Company also maintains an "overweight" rating on the stock, which indicates that the company believes the stock will outperform its peers in the market. The brokerage firm's target price of $23.00 represents a potential upside of 30.68% from the current stock price.

It is important to note that this information is based on the report issued by Wells Fargo & Company and should be considered as an opinion, not as a fact. Investors should always conduct their own research and consider seeking advice from a financial advisor before making any investment decisions.